Tomimoto Kazuya, Fujita Yasuko, Iwaki Tomoko, Chiba Yasunori, Jigami Yoshifumi, Nakayama Ken-ichi, Nakajima Yoshihiro, Abe Hiroko
Health Research Institute, National Institute of Advanced Industrial Science and Technology (AIST).
Biosci Biotechnol Biochem. 2013;77(12):2461-6. doi: 10.1271/bbb.130588. Epub 2013 Dec 7.
Saccharomyces cerevisiae strains engineered previously to produce proteins with mammalian high mannose structures showed severe growth defects and decreased protein productivity. In strain YAB101, derived from one of these strains by a mutagenesis technique based on the disparity theory of evolution, these undesirable phenotypes were alleviated. Here we describe further engineering of YAB101 with the aim of synthesizing heterologous glycoproteins with Man5GlcNAc2, an intermediate for the mammalian hybrid and complex type oligosaccharides. About 60% conversion of Man8GlcNAc2 to Man5GlcNAc2 was observed after integration of Aspergillus saitoi α-1,2-mannosidase fused to the transmembrane domain of S. cerevisiae Och1. To obtain a higher yield of the target protein, a protease-deficient version of this strain was generated by disruption of PEP4 and PRB1, resulting in YAB101-4. Inactivation of these vacuolar proteases enhanced the secretion of human interferon-β by approximately 10-fold.
先前经过基因工程改造以产生具有哺乳动物高甘露糖结构蛋白质的酿酒酵母菌株表现出严重的生长缺陷和蛋白质生产力下降。在基于进化差异理论的诱变技术从这些菌株之一衍生而来的YAB101菌株中,这些不良表型得到了缓解。在此,我们描述了对YAB101的进一步工程改造,目的是合成具有Man5GlcNAc2的异源糖蛋白,Man5GlcNAc2是哺乳动物杂合型和复合型寡糖的中间体。在整合了与酿酒酵母Och1跨膜结构域融合的斋藤曲霉α-1,2-甘露糖苷酶后,观察到约60%的Man8GlcNAc2转化为Man5GlcNAc2。为了获得更高产量的目标蛋白,通过破坏PEP4和PRB1产生了该菌株的蛋白酶缺陷型,即YAB101-4。这些液泡蛋白酶的失活使人类干扰素-β的分泌增加了约10倍。